Efficacy of etanercept in the treatment of a patient with Behçet's disease

Clinical Rheumatology

Volumn 27, Issue 7, 2008, Pages 933-936

  Curigliano, Valentina ^a   Giovinale, Maria ^a   Fonnesu, Claudia ^a   Cerquaglia, Claudia ^a   Verrecchia, Elena ^a   Turco, Simona ^a   Manganelli, Chiara ^a   Manna, Raffaele ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Beh et's disease; Etanercept

Indexed keywords

ANTIGLAUCOMA AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; ETANERCEPT; METHYLPREDNISOLONE; MIOTIC AGENT; PREDNISONE; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTHRALGIA; ARTICLE; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLICULITIS; HUMAN; INTRAOCULAR HYPERTENSION; LABORATORY TEST; MALE; OPHTHALMOSCOPY; PAPILLITIS; PERIARTERITIS; PHLEBITIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA VASCULITIS; SEROLOGY; SKIN MANIFESTATION; TREATMENT DURATION; UVEITIS; VASCULITIS;

ADULT; BEHCET SYNDROME; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 45049086684     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0857-5     Document Type: Article

References (11)

1. Gul A (2007) Standard and novel therapeutic approaches to Behçet's disease. Drugs 67:2013-2022
2. Suzuki Kurokawa M, Suzuki N (2004) Behcet's disease. Clin Exp Med 4:10-20
3. Sfikasis PP (2002) Behçet's disease: A new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):51-53
4. Papp Ka, Keystone EC, Shear NH (2007) Mechanism of action, pharmacolokinetic and drug interection of Etanercept. Dermatology 11(Suppl 1):3-13
5. Scallon B, Cai A, Solowski N et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426
6. Pipitone N, Olivieri I, Cantini F et al (2006) New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 18:3-9
7. Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368
8. Lee H, Kimko HC, Rogge M et al (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365
9. Korth-Bradley JM, Rubin AS, Hanna RK et al (2003) The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 34:161-164
10. Zhou H (2005) Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490-497
11. Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 32:98-105